Olmetec Plus

Olmesartan medoxomil 20 mg, hydrochlorothiazide 12.5 mg

HTN. Patients whose BP is not adequately controlled by olmesartan medoxomil or hydrochlorothiazide alone.

Adult Once daily.

May be taken with or without food.

Hypersensitivity to olmesartan medoxomil, hydrochlorothiazide, or other sulphonamide-derived substances. Anuria. Do not co-administer w/ aliskiren in patients w/ diabetes. Pregnancy.

Symptomatic hypotension may occur following initiation of treatment in vol &/or Na-depleted patients. Increased risk of renal insufficiency in patients w/ bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney. Risk of non-melanoma skin cancer. Limit exposure to sunlight & UV rays to minimize the risk of skin cancer. Not recommended in patients w/ more severe renal disease (CrCl <30 mL/min). Lactation. Childn & adolescents. Olmesartan medoxomil: Sprue-like enteropathy. Hyperkalemia; monitor serum electrolytes periodically. Hydrochlorothiazide: May precipitate azotemia in patients w/ renal disease. Idiosyncratic reaction resulting in acute transient myopia & acute angle-closure glaucoma. Minor alterations of fluid & electrolyte balance during therapy may precipitate hepatic coma in patients w/ impaired hepatic function or progressive liver disease. Hypersensitivity reaction in patients w/ or w/o history of allergy or bronchial asthma. Exacerbation or activation of SLE. Combination w/ lithium. May impair glucose tolerance; latent DM may manifest during therapy. Increases cholesterol & triglyceride levels. Hyperuricemia may occur or frank gout may precipitate. Perform periodic determination of serum electrolytes at appropriate intervals. Hypokalemia especially in patients w/ liver cirrhosis, experiencing brisk diuresis, receiving inadequate oral intake of electrolytes, & in concomitant therapy w/ corticosteroids or ACTH. Discontinue prior to parathyroid function test. Hypomagnesemia.

Olmesartan medoxomil: Dizziness. Hydrochlorothiazide: Gastric irritation, sialadenitis, pancreatitis; jaundice (intrahepatic cholestatic jaundice); xanthopsia, transient blurred vision; leukopenia, agranulocytosis, thrombocytopenia, aplastic & hemolytic anemia; photosensitivity reactions, urticaria, necrotizing angiitis (vasculitis, cutaneous vasculitis), anaphylactic reactions, TEN; fever; resp distress (including pneumonitis & pulmonary edema); renal dysfunction, interstitial nephritis; muscle spasms, weakness; restlessness; non-melanoma skin cancer especially squamous cell carcinoma in white patients; hyperglycemia, glycosuria, hyperuricemia, electrolyte imbalance (including hyponatremia & hypokalemia), increases in cholesterol & triglycerides.

Increased BP lowering effect w/ other antihypertensives. Increased serum conc & toxicity of lithium. Olmesartan medoxomil: Increased risks of hypotension, hyperkalemia, & changes in renal function (including acute renal failure) w/ ACE inhibitors & aliskiren. May increase risk of worsening renal function & attenuated antihypertensive effect w/ NSAIDs including COX-2 inhibitors. Reduced systemic exposure & peak plasma conc w/ colesevelam HCl. Hydrochlorothiazide: Potentiation of orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetics (oral agents & insulin). Impaired absorption w/ cholestyramine & colestipol resins. Greater risk of hypokalemia w/ corticosteroid & ACTH. May decrease effect of pressor amines (eg, noradrenaline). May potentiate effect of non-depolarizing skeletal muscle relaxants (eg, tubocurarine). Reduced diuretic, natriuretic & antihypertensive effects w/ NSAIDs.

Angiotensin II Antagonists / Diuretics

C09DA08 - olmesartan medoxomil and diuretics ; Belongs to the class of angiotensin II receptor blockers (ARBs) in combination with diuretics. Used in the treatment of cardiovascular disease.

Rx